

AMENDMENTS TO THE CLAIMS

This **listing of claims** will replace all prior versions, and listings, of the claims in the application.

Listing of Claims

1-144. (Canceled)

145. (Currently Amended) A method of treating a transplant recipient or preventing transplant rejection in a transplant recipient, comprising administering to the recipient an effective amount of an immunoglobulin specific to B7-1 and an effective amount of an immunoglobulin specific to B7-2, further including administering a third agent selected from the group consisting of: calcineurin inhibitor, steroid, and immunosuppressive agent that arrest the growth of immune cells, methotrexate, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof, and wherein an inhibitor of the CD40 /or CD40 ligand costimulatory interaction is not administered to the transplant recipient.

146. (Canceled)

147. (Currently Amended) The method of Claim 145 ~~146~~, wherein cyclosporin A or FK506 is administered.

148. (Canceled)

149. (Currently Amended) The method of Claim 145 ~~146~~, wherein rapamycin is administered.

150. (Previously Presented) The method of Claim 145, wherein the immunoglobulin specific to B7-1 is administered in an amount between about 1 mg/kg and about 25 mg/kg, and the immunoglobulin specific to B7-2 is administered in an amount between about 1 mg/kg and about 25 mg/kg.

151. (Previously Presented) The method of Claim 150, wherein the immunoglobulin specific to B7-1 and the immunoglobulin specific to B7-2 are administered on the day the recipient receives the transplantation.

152. (Previously Presented) The method of Claim 149, wherein the humanized immunoglobulin specific to B7-1 and the humanized immunoglobulin specific to B7-2 are further administered periodically after the recipient receives the transplantation.

153. (Previously Presented) The method of Claim 152, wherein the humanized immunoglobulin specific to B7-1 is administered between about 1 mg/kg and about 5 mg/kg, and the humanized immunoglobulin specific to B7-2 is administered between about 1 mg/kg and about 5 mg/kg at least weekly after the recipient receives the transplantation.

154. (Currently Amended) A method of modulating an immune response of an individual having a transplanted organ, tissue, cell or the like comprising administering an effective amount of the humanized immunoglobulin specific to B7-1, an effective amount of a humanized immunoglobulin specific to B7-2 in a carrier and administering a drug that is used to modulate the immune response of an individual having a transplanted organ, tissue, or cell, wherein the drug is selected from the group consisting of: methotrexate, rapamycin, cyclosporin, steroids, transplant salvage pathway inhibitor, IL-2 receptor antagonist, and analogs thereof, and wherein an inhibitor of the CD40 /~~or~~CD40 ligand costimulatory interaction is not administered to the individual.

155-160. (Canceled)